ArticleAddictive behaviors reports2026
US drug overdose deaths involving stimulants without opioids continued to rise in 2024.
Article in Addictive behaviors reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Background: After two decades of persistent growth, US drug overdose deaths (DODs) declined sharply in 2024, largely driven by reductions in fentanyl-involved mortality. However, trends in DODs involving stimulants without opioids remain less characterized and may follow distinct patterns. Methods: We analyzed aggregated data on unintentional DODs from 2018 to 2024 using the CDC data. Age-adjusted DOD rates were calculated using the 2000 US standard population. Joinpoint regression was used to identify significant temporal changes in mortality trends across substance categories. We examined percent changes in rates from 2023 to 2024 for cocaine and methamphetamine DODs without opioids, stratified by race/ethnicity, age group, and US census region. Results: Nationally, DOD rates declined by 27.9% from their 2022 peak to 2024, paralleling reductions in fentanyl-involved deaths. In contrast, rates of DODs involving stimulants without opioids increased slightly (cocaine: +1.7%; methamphetamine: +2.4%) from 2023 to 2024. Increases were observed nationally among White populations for cocaine without opioids and among Black, American Indian/Alaska Native (AIAN), and 55+ populations for methamphetamine without opioids. The Northeast experienced the largest increases for stimulant-without-opioid deaths, while the Midwest showed pronounced racial/ethnic divergence, including increases among White populations but substantial declines among Hispanic populations. Methamphetamine-without-opioid DODs rose markedly among AIAN populations in some regions. Conclusion: These findings highlight an evolving overdose crisis and underscore the need for prevention strategies that extend beyond opioid-focused interventions to address stimulant-specific harms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.